Impact of parity and delivery mode on pelvic floor function in young women: a 3D ultrasound evaluation.

INTRODUCTION AND HYPOTHESIS: The objectives were to evaluate clinical and anatomical parameters assessed by three-dimensional pelvic floor ultrasound (3D ultrasound) in parous and nulliparous women of childbearing age and to assess underreported symptoms of sexual dysfunction (SD), urinary incontinence (UI) and flatus incontinence (FI). METHODS: Women without complaints of pelvic floor dysfunction, aged 20-50 years, were eligible for this prospective cross-sectional study. They completed the King's Health Questionnaire, Female Sexual Function Index and St Mark's Incontinence Score adapted for this study. Next, a physical examination and 3D ultrasound were performed. The scores obtained in the questionnaires were compared with the 3D ultrasound data. RESULTS: In total, 326 women were invited to participate. Of these, 203 women met the inclusion criteria, and their cases were classified as nulliparity (NU, 59), vaginal delivery (VD, 80), forceps delivery (FD, 18) and caesarean section (CS, 48). These groups were homogeneous regarding age (p=0.096), parity (p=0.051) and body mass index (p=0.06). The hiatal dimension (HD; p=0.003) and transverse diameter (TD) (p=0.001) were significantly different among the groups. Compared with the NU and CS groups, the VD and FD groups had an increased HD and TD. The frequencies of underreported symptoms identified by questionnaires were as follows: SD (46.3%), UI (35%) and FI (28%). After VD and FD, women were more likely to present UI (p<0.001), FI (p<0.001) and SD (p=0.002) than the women with NU and those who had undergone a CS. UI was related to a greater HD (p=0.002) and anteroposterior diameter (p=0.022), FI was associated with a thinner left pubovisceral muscle (p=0.013), and SD was related to a greater HD (p=0.026). CONCLUSIONS: Three-dimensional ultrasound can identify mild morphological changes in young women with apparently normal physical examinations, mainly after VD and FD. In such individuals, these findings are associated with higher incidences of underreported sexual, urinary and anal symptoms.

Evaluation of tibolone effect on arterial resistance in postmenopausal women.

OBJECTIVE: The aim of this study was to evaluate the effect of tibolone on peripheral vascular resistance in postmenopausal women, by determination of the pulsatility index (PI) of the common carotid, radial and popliteal arteries using Doppler ultrasonography. METHODS: Twenty-nine patients were studied in a longitudinal, prospective, before and after study, for 7 months. The patients did not suffer from cardiovascular disease or any other conditions that would interfere with vascular resistance, and had no contraindications for hormone replacement therapy (HRT). Tibolone was used in a dose of 2.5 mg, orally, continuously for 6 months. Color duplex Doppler ultrasonography of the right and left common carotid, radial and popliteal arteries was carried out to determine PI, using the average value found in both sides at baseline (before administration of the drug), 3 and 6 months after initiating medication and 1 month after discontinuation of the drug. PI was determined by means of spectral analysis of the best arterial blood flow waveform, and pretreatment values (baseline) were used as control. RESULTS: In the common carotid artery, no significant differences in PI were observed at 3 and 6 months, in comparison with baseline. A significant decrease in PI was noted in the radial artery at 6 months as compared with baseline (decrease of 51.5%). PI in the popliteal artery also presented a significant decrease at 6 months in relation to baseline (decrease of 28.6%). The results were statistically assessed by ANOVA (analysis of variance). CONCLUSION: There was no significant variance in PI in the common carotid artery; however, in the radial and popliteal arteries there was significant variance, and their resistance decreased after use of tibolone for 6 months but returned to the pretreatment values 1 month after discontinuation of the drug.